Pharmacokinetic/pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent

被引:109
作者
Meagher, AK [1 ]
Ambrose, PG
Grasela, TH
Ellis-Grosse, EJ
机构
[1] Cognigen Corp, Dept Clin Pharmacol, Buffalo, NY 14221 USA
[2] Ordway Inst, Inst Clin Pharmacodynam, Albany, NY USA
[3] Dept Wyeth Res, Collegeville, PA USA
关键词
tigecycline; pharmacology; pharmacokinetics;
D O I
10.1016/j.diagmicrobio.2005.05.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Tigecycline is a new first-in-class glycylcycline antimicrobial agent with expanded broad-spectrum activity against both Gram-negative and Gram-positive aerobes and anaerobes, as well as atypical bacterial species. The spectrum of activity extends to clinically relevant susceptible and multidrug-resistant strains of Staphylococcus aureus, Streptococcus Pneumoniae, vancomycin-resistant enterococci, and Enterobacteriaceae, including extended-spectrum beta-lactamase-producing strains. Tigecycline is administered as an intravenous formulation and has been studied in the treatment of serious polymicrobial infections, including complicated: skin and skin-structure infections and intra-abdominal infections. Pharmacokinetic analysis of data from phase 1 trials of healthy subjects indicate that tigecycline has a large volume of distribution, signifying extensive tissue penetration, and a long terminal elimination half-life (approximately 40 h), easily allowing for twice-daily dose administration. Tigecycline penetrates well into blister fluid, which supports the positive findings of phase 2 and 3 studies of the efficacy of tigecycline in the treatment of serious skin and skin-structure infections. Metabolic studies in humans have revealed that tigecycline undergoes very limited metabolism and the primary route of elimination of unchanged drug is through the feces, with glucuronidation and renal elimination as secondary routes. A preliminary pharmacokinetic (PK)/pharmacodynamic analysis in experimental animal models of infection indicates that the efficacy of tigecycline is probably best predicted by the ratio of the area under the concentration-time curve to the minimum inhibitory concentration. The expanded in vitro activity against a broad range of bacteria, including resistant pathogens, and favourable PK profile of tigecycline suggest that this novel antimicrobial agent should offer clinicians an option for the treatment of patients with serious bacterial infections. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:165 / 171
页数:7
相关论文
共 39 条
[1]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]   In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases [J].
Biedenbach, DJ ;
Beach, ML ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 40 (04) :173-177
[3]   In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria [J].
Boucher, HW ;
Wennersten, CB ;
Eliopoulos, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2225-2229
[4]   In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides [J].
Cercenado, E ;
Cercenado, S ;
Gómez, JA ;
Bouza, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :138-139
[5]   DRUG DIFFUSION AND BIOAVAILABILITY - TETRACYCLINE METALLIC CHELATION [J].
CHIN, TF ;
LACH, JL .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1975, 32 (06) :625-629
[6]  
CHRISTIANSON J, 2001, 41 ICCAC ABSTR CHIC
[7]  
Clinical and Laboratory Standards, 2005, PERF STAND ANT SUSC
[8]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[9]  
Edlund C, 2000, CLIN MICROBIOL INFEC, V6, P158
[10]   INTERACTION OF TETRACYCLINES WITH RIBOSOMAL-SUBUNITS FROM ESCHERICHIA-COLI - FLUOROMETRIC INVESTIGATION [J].
FEY, G ;
REISS, M ;
KERSTEN, H .
BIOCHEMISTRY, 1973, 12 (06) :1160-1164